Cargando…

Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths

Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kropp, Peter A., Bauer, Rosemary, Zafra, Isabella, Graham, Carina, Golden, Andy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380043/
https://www.ncbi.nlm.nih.gov/pubmed/34370008
http://dx.doi.org/10.1242/dmm.049010
_version_ 1783741117725933568
author Kropp, Peter A.
Bauer, Rosemary
Zafra, Isabella
Graham, Carina
Golden, Andy
author_facet Kropp, Peter A.
Bauer, Rosemary
Zafra, Isabella
Graham, Carina
Golden, Andy
author_sort Kropp, Peter A.
collection PubMed
description Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundation and provide the opportunity for understanding their mechanisms and phenotypes, as well as potential treatments. One strategy for effectively and efficiently studying rare diseases is using genetically tractable organisms to model the disease and learn about the essential cellular processes affected. Beyond investigating dysfunctional cellular processes, modeling rare diseases in simple organisms presents the opportunity to screen for pharmacological or genetic factors capable of ameliorating disease phenotypes. Among the small model organisms that excel in rare disease modeling is the nematode Caenorhabditis elegans. With a staggering breadth of research tools, C. elegans provides an ideal system in which to study human disease. Molecular and cellular processes can be easily elucidated, assayed and altered in ways that can be directly translated to humans. When paired with other model organisms and collaborative efforts with clinicians, the power of these C. elegans studies cannot be overstated. This Review highlights studies that have used C. elegans in diverse ways to understand rare diseases and aid in the development of treatments. With continuing and advancing technologies, the capabilities of this small round worm will continue to yield meaningful and clinically relevant information for human health.
format Online
Article
Text
id pubmed-8380043
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Company of Biologists Ltd
record_format MEDLINE/PubMed
spelling pubmed-83800432021-08-31 Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths Kropp, Peter A. Bauer, Rosemary Zafra, Isabella Graham, Carina Golden, Andy Dis Model Mech Review Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundation and provide the opportunity for understanding their mechanisms and phenotypes, as well as potential treatments. One strategy for effectively and efficiently studying rare diseases is using genetically tractable organisms to model the disease and learn about the essential cellular processes affected. Beyond investigating dysfunctional cellular processes, modeling rare diseases in simple organisms presents the opportunity to screen for pharmacological or genetic factors capable of ameliorating disease phenotypes. Among the small model organisms that excel in rare disease modeling is the nematode Caenorhabditis elegans. With a staggering breadth of research tools, C. elegans provides an ideal system in which to study human disease. Molecular and cellular processes can be easily elucidated, assayed and altered in ways that can be directly translated to humans. When paired with other model organisms and collaborative efforts with clinicians, the power of these C. elegans studies cannot be overstated. This Review highlights studies that have used C. elegans in diverse ways to understand rare diseases and aid in the development of treatments. With continuing and advancing technologies, the capabilities of this small round worm will continue to yield meaningful and clinically relevant information for human health. The Company of Biologists Ltd 2021-08-09 /pmc/articles/PMC8380043/ /pubmed/34370008 http://dx.doi.org/10.1242/dmm.049010 Text en © 2021. Published by The Company of Biologists Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle Review
Kropp, Peter A.
Bauer, Rosemary
Zafra, Isabella
Graham, Carina
Golden, Andy
Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
title Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
title_full Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
title_fullStr Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
title_full_unstemmed Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
title_short Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
title_sort caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380043/
https://www.ncbi.nlm.nih.gov/pubmed/34370008
http://dx.doi.org/10.1242/dmm.049010
work_keys_str_mv AT kropppetera caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths
AT bauerrosemary caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths
AT zafraisabella caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths
AT grahamcarina caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths
AT goldenandy caenorhabditiselegansforrarediseasemodelinganddrugdiscoverystrategiesandstrengths